Table 2.

mTSS non-progression analysis

		mTSS non-progressor rate (%)
Non-progressor cut-off (mTSS)	Imputation of missing values	Placebo (n=136)	CZP 200 mg Q2W (n=138)	CZP 400 mg Q4W (n=135)
0†	≥2 mTSS: NRI‡§ <2 mTSS: considered progressors‡	34.6	83.3*	76.3*
0†	≥2 mTSS: linear imputation <2 mTSS: no imputation	81.9	91.7*	87.8
≤0.5	≥2 mTSS: linear imputation <2 mTSS: no imputation	86.6	96.2*	96.7*
≤0.5	≥2 mTSS: linear imputation <2 mTSS: mean mTSS change from BL of all patients observed	87.5	96.4*	97.0*
≤0.5	≥2 mTSS: linear imputation <2 mTSS: median mTSS change from BL of all patients observed	87.5	96.4*	97.0*
≤0.5	≥2 mTSS: linear imputation <2 mTSS: maximum mTSS change from BL of all patients observed	79.4	92.8*	88.1

For placebo patients who escaped early to CZP, the week 24 values were linearly extrapolated.

*p<0.05 versus placebo.

†Prespecified non-progressor cut-off mTSS.

‡Prespecified imputation.

§Patients with missing values considered progressors.

BL, baseline; CZP, certolizumab pegol; mTSS, modified Total Sharp Score; NRI, non-responder imputation; Q2W, every 2 weeks; Q4W, every 4 weeks.